HTGF in €8m series-B for Amal Therapeutics

The round was co-led by corporate venture capital firms Boehringer Ingelheim Venture Fund (BIVF), BioMedPartners and Helsinn Investment Fund.

Financial backers VI Partners and Schroder Adveq also invested in the round.

The fresh capital will be used to support clinical development of the lead vaccine for colorectal cancer through to clinical proof-of-concept. The company will also focus on the further development of its Kisima technology platform.

Previous funding
In February 2013, BIVF and HTGF invested in a seed round for Amal Therapeutics in order to progress its first vaccine candidate to the pre-clinical development stage.

In March 2016, both investors backed a CHF 3m series-A round alongside VI Partners to further develop the platform.

Company
Amal Therapeutics is a Swiss biotech company that was incorporated in 2012 as a spinout from the University of Geneva. The company develops Kisima, a proprietary vaccine technology platform dedicated to oncology indications.

People
High-Tech Gründerfonds – Frank Hensel (senior investment manager).
Amal Therapeutics – Madiha Derouazi (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Switzerland
• High-Tech Gründerfonds